Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

SRx Health Solutions (SRXH) EBITDA (2016 - 2025)

SRx Health Solutions' EBITDA history spans 16 years, with the latest figure at -$26.9 million for Q2 2025.

  • For Q2 2025, EBITDA fell 565.17% year-over-year to -$26.9 million; the TTM value through Jun 2025 reached -$20.6 million, down 71.67%, while the annual FY2024 figure was $4.2 million, 119.79% up from the prior year.
  • EBITDA reached -$26.9 million in Q2 2025 per SRXH's latest filing, down from -$1.1 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $8.5 million in Q4 2024 to a low of -$26.9 million in Q2 2025.
  • Average EBITDA over 5 years is -$5.3 million, with a median of -$3.6 million recorded in 2022.
  • Peak YoY movement for EBITDA: surged 323.91% in 2024, then plummeted 565.17% in 2025.
  • A 5-year view of EBITDA shows it stood at -$5.0 million in 2021, then plummeted by 385.37% to -$24.2 million in 2022, then skyrocketed by 47.33% to -$12.7 million in 2023, then skyrocketed by 166.89% to $8.5 million in 2024, then tumbled by 416.38% to -$26.9 million in 2025.
  • Per Business Quant, the three most recent readings for SRXH's EBITDA are -$26.9 million (Q2 2025), -$1.1 million (Q1 2025), and $8.5 million (Q4 2024).